ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Menasché, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menasché, P.
Related Collections
Right arrow Molecular biology

Ann Thorac Surg 2003;75:S20-S28
© 2003 The Society of Thoracic Surgeons

Supplement

Cell transplantation in myocardium

Philippe Menasché, MD, PhDa*

a Department of Cardiovascular Surgery, Hôpital Européen Georges Pompidou, Paris, France

* Address reprint requests to Dr Menasché, Department of Cardiovascular Surgery, Hôpital Européen Georges Pompidou, 20, rue Leblanc, 75015 Paris, France
e-mail: philippe.menasche{at}hop.egp.ap-hop-paris.fr

Presented at the Heart Failure & Circulatory Support Summit, Cleveland, OH, Aug 22–25, 2002.

Abstract

Cell transplantation is gaining a growing interest as a potential new means of improving the prognosis of patients with cardiac failure. The basic assumption is that left ventricular dysfunction is largely due to the loss of a critical number of cardiomyocytes and that it can be partly reversed by implantation of new contractile cells into the postinfarction scars. Primarily for practical reasons, autologous skeletal myoblasts have been the first to undergo clinical trials but other cell types are also considered, particularly bone marrow stem cells, which are attractive because of their autologous origin and their purported cardiomyocyte/endothelial transdifferentiation potential in response to cues provided by the target organ. However several key issues still need to be addressed including (1) the optimal type of donor cells, (2) the mechanism by which cell engraftment improves cardiac function, (3) the optimization of cell survival, and (4) the potential benefits of cell transplantation in nonischemic heart failure. In parallel to the experimental studies designed to address these issues clinical trials are under way and should hopefully allow assessing to what extent cell transplantation may improve the outcome of patients with heart failure.




This article has been cited by other articles:


Home page
 Stem CellsHome page
G. Forte, F. Carotenuto, F. Pagliari, S. Pagliari, P. Cossa, R. Fiaccavento, A. Ahluwalia, G. Vozzi, B. Vinci, A. Serafino, et al.
Criticality of the Biological and Physical Stimuli Array Inducing Resident Cardiac Stem Cell Determination
Stem Cells, August 1, 2008; 26(8): 2093 - 2103.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
T. Siminiak, E. Meliga, O. Jerzykowska, and P. W. Serruys
Percutaneous transplantation of skeletal myoblast in the treatment of post-infarction injury
Eur. Heart J. Suppl., December 1, 2006; 8(suppl_H): H57 - H64.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
H. Hata, G. Matsumiya, S. Miyagawa, H. Kondoh, N. Kawaguchi, N. Matsuura, T. Shimizu, T. Okano, H. Matsuda, and Y. Sawa
Grafted skeletal myoblast sheets attenuate myocardial remodeling in pacing-induced canine heart failure model
J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 918 - 924.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. E. Davis, P. C. H. Hsieh, T. Takahashi, Q. Song, S. Zhang, R. D. Kamm, A. J. Grodzinsky, P. Anversa, and R. T. Lee
Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction
PNAS, May 23, 2006; 103(21): 8155 - 8160.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. N. Patel, L. Geffner, R. F. Vina, J. Saslavsky, H. C. Urschel Jr, R. Kormos, and F. Benetti
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study
J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1631 - 1638.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
N. Borenstein, Z. Jian, G. Fromont, P. Bruneval, M. Hekmati, L. Behr, F. Laborde, D. Montarras, and E. Le Bret
Noncultured cell transplantation in an ovine model of right ventricular preparation
J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1119 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. A. Narmoneva, R. Vukmirovic, M. E. Davis, R. D. Kamm, and R. T. Lee
Endothelial Cells Promote Cardiac Myocyte Survival and Spatial Reorganization: Implications for Cardiac Regeneration
Circulation, August 24, 2004; 110(8): 962 - 968.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
H. C. Ott, S. Berjukow, R. Marksteiner, E. Margreiter, G. Bock, G. Laufer, and S. Hering
On the fate of skeletal myoblasts in a cardiac environment: down-regulation of voltage-gated ion channels
J. Physiol., August 1, 2004; 558(3): 793 - 805.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The Society of Thoracic Surgeons.